Kornitzer Capital Management Inc. KS Acquires Shares of 2,000 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Kornitzer Capital Management Inc. KS purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 2,000 shares of the biopharmaceutical company's stock, valued at approximately $540,000.

Other hedge funds have also added to or reduced their stakes in the company. Whipplewood Advisors LLC lifted its stake in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 71 shares during the period. Bessemer Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares during the period. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $28,000. Colonial Trust Co SC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. Finally, Washington Trust Advisors Inc. raised its position in shares of Alnylam Pharmaceuticals by 53.5% during the first quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company's stock worth $47,000 after purchasing an additional 61 shares during the period. Institutional investors own 92.97% of the company's stock.

Analyst Ratings Changes

ALNY has been the topic of a number of research analyst reports. Canaccord Genuity Group raised their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a research report on Friday, March 21st. Morgan Stanley dropped their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a research report on Friday, April 11th. HC Wainwright reaffirmed a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the company an "equal weight" rating in a research report on Monday, June 30th. Finally, UBS Group lifted their target price on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and twenty-two have issued a buy rating to the company's stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $346.13.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded down $4.16 during midday trading on Friday, hitting $320.53. 581,106 shares of the company's stock were exchanged, compared to its average volume of 852,651. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $333.70. The company's 50 day moving average price is $305.09 and its 200 day moving average price is $270.94. The firm has a market capitalization of $41.79 billion, a PE ratio of -153.36 and a beta of 0.23.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The business's revenue was up 20.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the transaction, the chief executive officer directly owned 48,948 shares of the company's stock, valued at $14,978,088. The trade was a 28.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.